Clark W F, Jevnikar A M
Division of Nephrology, London Health Sciences Centre, Ontario, Canada.
Semin Nephrol. 1999 Jan;19(1):77-85.
The 1975 observations of the Advisory Committee of the Renal Transplant Registry about systemic lupus erythematosus (SLE) remain largely unaltered. The SLE patient's survival after renal transplantation has improved, but remains similar to the non-SLE transplantation population. Disease activity declines throughout the transplantation period with a low rate of graft loss due to recurrent disease. There is slight discordant evidence about spontaneous renal recovery and graft survival rates in the SLE transplant population. The latter difference may relate to variances in the donor source (live-related versus cadaveric). The original report did not address the now well-recognized immediate- and long-term risks posed by the anti-phospholipid antibody syndrome, the accelerated rate of vascular disease, hematologic malignancies, and corticosteroid osteoporosis in the SLE transplant recipient.
肾脏移植登记咨询委员会1975年对系统性红斑狼疮（SLE）的观察结果在很大程度上仍未改变。SLE患者肾移植后的生存率有所提高，但仍与非SLE移植人群相似。在整个移植期间疾病活动度下降，因疾病复发导致的移植物丢失率较低。关于SLE移植人群中自发肾脏恢复和移植物存活率存在一些不一致的证据。后一种差异可能与供体来源（亲属活体供肾与尸体供肾）的差异有关。最初的报告没有涉及现在已广为人知的SLE移植受者中抗磷脂抗体综合征、血管疾病加速、血液系统恶性肿瘤和皮质类固醇性骨质疏松所带来的近期和长期风险。
